Organogenesis Holdings Inc. Reports Second Quarter 2024 Financial Results
Organogenesis Holdings Inc. (Nasdaq: ORGO) reported financial results for Q2 2024, ending June 30. Net revenue increased to $130.2 million, up from $117.3 million in Q2 2023. This growth was primarily driven by a 12% increase in revenue from Advanced Wound Care products, totaling $123.2 million. However, revenue from Surgical & Sports Medicine products dropped 3% to $7.0 million.
The net loss for Q2 2024 was $17.0 million, compared to a net income of $5.3 million in Q2 2023. Adjusted net income also fell to $0.2 million, down from $6.1 million. Operating expenses surged by 41% to $114.9 million, primarily due to increased R&D and selling costs.
For the first half of 2024, net revenue was $240.2 million, an increase of 7% from the same period in 2023. The company reaffirmed its 2024 revenue guidance of $445.0 million to $470.0 million and adjusted its profitability guidance.
Organogenesis Holdings Inc. (Nasdaq: ORGO) ha riportato i risultati finanziari per il secondo trimestre del 2024, conclusosi il 30 giugno. Il fatturato netto è aumentato a 130,2 milioni di dollari, rispetto ai 117,3 milioni di dollari del secondo trimestre del 2023. Questa crescita è stata trainata principalmente da un aumento del 12% delle entrate dai prodotti per la cura avanzata delle ferite, pari a 123,2 milioni di dollari. Tuttavia, le entrate dai prodotti di Medicina Chirurgica e Sportiva sono diminuite del 3%, raggiungendo 7,0 milioni di dollari.
La perdita netta per il secondo trimestre del 2024 è stata di 17,0 milioni di dollari, rispetto a un utile netto di 5,3 milioni di dollari nel secondo trimestre del 2023. Anche l'utile netto rettificato è sceso a 0,2 milioni di dollari, rispetto ai 6,1 milioni di dollari precedenti. Le spese operative sono aumentate del 41%, raggiungendo 114,9 milioni di dollari, principalmente a causa dell'aumento dei costi di ricerca e sviluppo e di vendita.
Per la prima metà del 2024, il fatturato netto è stato di 240,2 milioni di dollari, con un aumento del 7% rispetto allo stesso periodo del 2023. L'azienda ha confermato la sua previsione di fatturato per il 2024 di 445,0 milioni di dollari a 470,0 milioni di dollari, e ha rettificato le sue previsioni di redditività.
Organogenesis Holdings Inc. (Nasdaq: ORGO) informó los resultados financieros para el segundo trimestre de 2024, finalizado el 30 de junio. Los ingresos netos aumentaron a 130,2 millones de dólares, en comparación con 117,3 millones de dólares en el segundo trimestre de 2023. Este crecimiento fue impulsado principalmente por un aumento del 12% en los ingresos de los productos de Cuidado Avanzado de Heridas, que totalizaron 123,2 millones de dólares. Sin embargo, los ingresos por productos de Medicina Quirúrgica y Deportiva cayeron un 3% hasta 7,0 millones de dólares.
La pérdida neta en el segundo trimestre de 2024 fue de 17,0 millones de dólares, en comparación con una ganancia neta de 5,3 millones de dólares en el segundo trimestre de 2023. Los ingresos netos ajustados también disminuyeron a 0,2 millones de dólares, desde 6,1 millones de dólares. Los gastos operativos aumentaron un 41%, alcanzando 114,9 millones de dólares, principalmente debido a mayores gastos en I+D y venta.
Para la primera mitad de 2024, los ingresos netos fueron de 240,2 millones de dólares, un aumento del 7% con respecto al mismo período de 2023. La compañía reafirmó su guía de ingresos para 2024 de entre 445,0 millones de dólares a 470,0 millones de dólares y ajustó su guía de rentabilidad.
Organogenesis Holdings Inc. (Nasdaq: ORGO)는 2024년 2분기 재무 결과를 보고했습니다. 6월 30일 기준으로 순수익은 1억 3,020만 달러로 증가하였으며, 이는 2023년 2분기의 1억 1,730만 달러에서 증가한 것입니다. 이 성장은 주로 고급 상처 치료 제품의 수익이 12% 증가하여 1억 2,320만 달러에 이르렀기 때문입니다. 그러나 외과 및 스포츠 의학 제품의 수익은 3% 감소하여 700만 달러에 그쳤습니다.
2024년 2분기의 순손실은 1,700만 달러로, 2023년 2분기의 순이익 530만 달러와 비교됩니다. 조정된 순이익도 20만 달러로 줄어들었으며, 이전의 610만 달러에서 감소했습니다. 운영비용은 연구개발 및 판매 비용 증가로 인해 41% 증가하여 1억 1,490만 달러에 달했습니다.
2024년 상반기 동안, 순수익은 2억 4,020만 달러로 2023년 같은 기간 대비 7% 증가했습니다. 회사는 2024년 수익 가이던스를 4억 4,500만 달러에서 4억 7,000만 달러로 확인하며, 수익성 가이던스도 조정했습니다.
Organogenesis Holdings Inc. (Nasdaq: ORGO) a publié ses résultats financiers pour le deuxième trimestre 2024, se terminant le 30 juin. Les revenus nets ont augmenté à 130,2 millions de dollars, contre 117,3 millions de dollars au deuxième trimestre 2023. Cette croissance a été principalement portée par une augmentation de 12% des revenus des produits de soins avancés des plaies, s'élevant à 123,2 millions de dollars. Cependant, les revenus des produits de médecine chirurgicale et sportive ont diminué de 3%, atteignant 7,0 millions de dollars.
La perte nette pour le deuxième trimestre 2024 s'élevait à 17,0 millions de dollars, contre un bénéfice net de 5,3 millions de dollars au deuxième trimestre 2023. Le bénéfice net ajusté a également chuté à 0,2 million de dollars, contre 6,1 millions de dollars. Les dépenses d'exploitation ont augmenté de 41% pour atteindre 114,9 millions de dollars, principalement en raison de l'augmentation des coûts de R&D et de vente.
Pour la première moitié de 2024, les revenus nets se sont élevés à 240,2 millions de dollars, soit une augmentation de 7% par rapport à la même période en 2023. L'entreprise a réaffirmé ses prévisions de revenus pour 2024 de 445,0 millions de dollars à 470,0 millions de dollars et a ajusté ses prévisions de rentabilité.
Organogenesis Holdings Inc. (Nasdaq: ORGO) berichtete über die Finanzzahlen für das zweite Quartal 2024, das am 30. Juni endete. Der Nettoerlös stieg auf 130,2 Millionen US-Dollar, ein Anstieg von 117,3 Millionen US-Dollar im zweiten Quartal 2023. Dieses Wachstum wurde hauptsächlich durch einen Umsatzanstieg von 12% bei Produkten für die fortschrittliche Wundversorgung, die insgesamt 123,2 Millionen US-Dollar ausmachten, vorangetrieben. Allerdings sank der Umsatz aus chirurgischen und sportmedizinischen Produkten um 3% auf 7,0 Millionen US-Dollar.
Der Nettoverlust für das zweite Quartal 2024 betrug 17,0 Millionen US-Dollar, im Vergleich zu einem Nettogewinn von 5,3 Millionen US-Dollar im zweiten Quartal 2023. Der bereinigte Nettogewinn fiel ebenfalls auf 0,2 Millionen US-Dollar, von 6,1 Millionen US-Dollar. Die Betriebskosten stiegen um 41% auf 114,9 Millionen US-Dollar, hauptsächlich aufgrund gestiegener F&E- und Vertriebskosten.
Für die erste Hälfte des Jahres 2024 betrugen die Nettoumsätze 240,2 Millionen US-Dollar, was einem Anstieg von 7% gegenüber dem gleichen Zeitraum im Jahr 2023 entspricht. Das Unternehmen bestätigte seine Umsatzprognose für 2024 in Höhe von 445,0 Millionen US-Dollar bis 470,0 Millionen US-Dollar und passte die Gewinnprognose an.
- Net revenue increased by $12.9 million (11%) year-over-year to $130.2 million.
- Advanced Wound Care product revenue grew by 12% to $123.2 million.
- Adjusted EBITDA increased slightly to $15.6 million from $15.4 million in Q2 2023.
- Net loss of $17.0 million for Q2 2024, compared to a net income of $5.3 million in Q2 2023.
- Operating expenses increased by 41% to $114.9 million.
- Revenue from Surgical & Sports Medicine products decreased by 3% to $7.0 million.
- Adjusted net income fell significantly to $0.2 million, down from $6.1 million in Q2 2023.
- Operating loss of $13.9 million, a decrease of $23.6 million compared to Q2 2023.
Insights
Organogenesis reported mixed Q2 2024 results, with revenue growth but a swing to net loss. Key points:
- Revenue increased
11% YoY to$130.2 million , driven by12% growth in Advanced Wound Care. - Gross margin held steady at
78% . - Net loss of
$17.0 million vs. net income of$5.3 million in Q2 2023, impacted by impairment charges. - Adjusted EBITDA slightly up at
$15.6 million .
The company maintained its FY2024 revenue guidance but lowered profitability expectations. While top-line growth is encouraging, the significant swing to losses raises concerns about cost management and profitability going forward.
The Q2 results highlight Organogenesis' continued focus on regenerative medicine, particularly in Advanced Wound Care. The
The increase in R&D expenses (
The challenging operating environment mentioned by management likely refers to competitive pressures and potential reimbursement issues in the skin substitutes market. This warrants close monitoring of market dynamics and regulatory developments.
Organogenesis' Q2 performance reveals both strengths and challenges in its market position. The
The company's guidance for FY2024, projecting
Management's comments about "near-term variability in the skin substitutes market" highlight the need for investors to closely monitor industry trends and competitive dynamics in this space.
CANTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the second quarter ended June 30, 2024.
Second Quarter 2024 Financial Results Summary:
- Net revenue of
$130.2 million for the second quarter of 2024, an increase of$12.9 million compared to net revenue of$117.3 million for the second quarter of 2023. Net revenue for the second quarter of 2024 consists of:- Net revenue from Advanced Wound Care products of
$123.2 million , an increase of12% from the second quarter of 2023. - Net revenue from Surgical & Sports Medicine products of
$7.0 million , a decrease of3% from the second quarter of 2023.
- Net revenue from Advanced Wound Care products of
- Net loss of
$17.0 million for the second quarter of 2024, compared to net income of$5.3 million for the second quarter of 2023, a decrease in net income of$22.4 million . - Adjusted net income¹ of
$0.2 million for the second quarter of 2024, compared to adjusted net income of$6.1 million for the second quarter of 2023, a decrease in adjusted net income of$5.9 million . - Adjusted EBITDA of
$15.6 million for the second quarter of 2024, compared to Adjusted EBITDA of$15.4 million for the second quarter of 2023, an increase of$0.2 million .
“Our progress in the second quarter reflects strong execution and validation of our strategy to expand customer relationships by emphasizing the value of our differentiated products,” said Gary S. Gillheeney, Sr., President and Chief Executive Officer of Organogenesis.
Mr. Gillheeney, Sr. continued: “We continue building momentum in a challenging operating environment while achieving major clinical milestones and advancing the ReNu development program. Although we expect near-term variability in the skin substitutes market, we are extremely pleased with our progress in the first half of the year and are confident in our ability to navigate that complexity while working to expand our extensive body of clinical evidence supporting meaningful solutions that improve patients’ lives.”
Second Quarter 2024 Financial Results:
| Three Months Ended June 30, | Change | |||||||||||||||
| 2024 | 2023 | $ | % | |||||||||||||
| (in thousands, except for percentages) | ||||||||||||||||
| Advanced Wound Care | $ | 123,237 | $ | 110,075 | $ | 13,162 | 12 | % | ||||||||
| Surgical & Sports Medicine | 6,997 | 7,241 | (244 | ) | (3 | %) | ||||||||||
| Net revenue | $ | 130,234 | $ | 117,316 | $ | 12,918 | 11 | % | ||||||||
| Six Months Ended June 30, | Change | |||||||||||||||
| 2024 | 2023 | $ | % | |||||||||||||
| (in thousands, except for percentages) | ||||||||||||||||
| Advanced Wound Care | $ | 227,101 | $ | 210,992 | $ | 16,109 | 8 | % | ||||||||
| Surgical & Sports Medicine | 13,109 | 13,966 | (857 | ) | (6 | %) | ||||||||||
| Net revenue | $ | 240,210 | $ | 224,958 | $ | 15,252 | 7 | % | ||||||||
Net revenue for the second quarter of 2024 was
Gross profit for the second quarter of 2024 was
Operating expenses for the second quarter of 2024 were
Operating loss for the second quarter of 2024 was
Total other expense, net, for the second quarter of 2024 was
Net loss for the second quarter of 2024 was
Adjusted net income of
Adjusted EBITDA was
As of June 30, 2024, the Company had
First Half 2024 Financial Results:
| Six Months Ended June 30, | Change | |||||||||||||||
| 2024 | 2023 | $ | % | |||||||||||||
| (in thousands, except for percentages) | ||||||||||||||||
| Advanced Wound Care | $ | 227,101 | $ | 210,992 | $ | 16,109 | 8 | % | ||||||||
| Surgical & Sports Medicine | 13,109 | 13,966 | (857 | ) | (6 | %) | ||||||||||
| Net revenue | $ | 240,210 | $ | 224,958 | $ | 15,252 | 7 | % | ||||||||
Net revenue for the six months ended June 30, 2024 was
Gross profit for the six months ended June 30, 2024 was
Operating expenses for the six months ended June 30, 2024 were
Operating loss for the six months ended June 30, 2024 was
Total other expense, net, for the six months ended June 30, 2024 was
Net loss for the six months ended June 30, 2024 was
Adjusted net loss of
Adjusted EBITDA was
As of June 30, 2024, the Company had
Fiscal Year 2024 Guidance:
For the year ending December 31, 2024 the Company is reaffirming its prior revenue guidance and updating its profitability guidance and expects:
- Net revenue between
$445.0 million and$470.0 million , representing an increase of approximately3% to9% year-over-year, as compared to net revenue of$433.1 million for the year ended December 31, 2023.- The 2024 net revenue guidance range assumes:
- Net revenue from Advanced Wound Care products between
$415.0 million and$435.0 million , an increase of2% to7% year-over-year as compared to net revenue of$405.5 million for the year ended December 31, 2023. - Net revenue from Surgical & Sports Medicine products between
$30.0 million and$35.0 million , an increase of9% to27% year-over-year as compared to net revenue of$27.6 million for the year ended December 31, 2023.
- Net revenue from Advanced Wound Care products between
- The 2024 net revenue guidance range assumes:
- Net loss between
$(27.0) million and$(12.0) million and adjusted net income (loss) between$(8.0) million and$7.0 million . - EBITDA between
$(17.0) million and$2.0 million and Adjusted EBITDA between$16.0 million and$35.0 million .
Second Quarter Earnings Conference Call:
Management will host a conference call at 5:00 p.m. Eastern Time on August 8th to discuss the results of the quarter, and provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast by visiting www.investors.organogenesis.com or by calling (800) 715-9871 and providing access code 6679912. The live webcast can also be accessed via the company's website at investors.organogenesis.com. The webcast will be archived on the company website for approximately one year.
| ORGANOGENESIS HOLDINGS INC. | ||||||||
| UNAUDITED CONSOLIDATED BALANCE SHEETS | ||||||||
| (amounts in thousands, except share and per share data) | ||||||||
| June 30, | December 31, | |||||||
| 2024 | 2023 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 89,902 | $ | 103,840 | ||||
| Restricted cash | 575 | 498 | ||||||
| Accounts receivable, net | 105,945 | 81,999 | ||||||
| Inventories, net | 26,883 | 28,253 | ||||||
| Prepaid expenses and other current assets | 10,889 | 10,454 | ||||||
| Total current assets | 234,194 | 225,044 | ||||||
| Property and equipment, net | 89,947 | 116,228 | ||||||
| Intangible assets, net | 14,136 | 15,871 | ||||||
| Goodwill | 28,772 | 28,772 | ||||||
| Operating lease right-of-use assets, net | 36,572 | 40,118 | ||||||
| Deferred tax asset, net | 33,691 | 28,002 | ||||||
| Other assets | 5,851 | 5,990 | ||||||
| Total assets | $ | 443,163 | $ | 460,025 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Current portion of term loan | $ | 5,758 | $ | 5,486 | ||||
| Current portion of finance lease obligations | 1,125 | 1,081 | ||||||
| Current portion of operating lease obligations - related party | 7,357 | 8,413 | ||||||
| Current portion of operating lease obligations | 4,081 | 4,731 | ||||||
| Accounts payable | 29,390 | 30,724 | ||||||
| Accrued expenses and other current liabilities | 38,016 | 30,074 | ||||||
| Total current liabilities | 85,727 | 80,509 | ||||||
| Term loan, net of current portion | 57,731 | 60,745 | ||||||
| Finance lease obligations, net of current portion | 1,314 | 1,888 | ||||||
| Operating lease obligations, net of current portion - related party | 10,139 | 11,954 | ||||||
| Operating lease obligations, net of current portion | 23,483 | 25,053 | ||||||
| Other liabilities | 1,268 | 1,213 | ||||||
| Total liabilities | 179,662 | 181,362 | ||||||
| Commitments and contingencies (Note 15) | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, | — | — | ||||||
| Common stock, | 13 | 13 | ||||||
| Additional paid-in capital | 323,602 | 319,621 | ||||||
| Accumulated deficit | (60,114 | ) | (40,971 | ) | ||||
| Total stockholders’ equity | 263,501 | 278,663 | ||||||
| Total liabilities and stockholders’ equity | $ | 443,163 | $ | 460,025 | ||||
| ORGANOGENESIS HOLDINGS INC. UNAUDITEDCONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | ||||||||||||||||
| (amounts in thousands, except share and per share data) | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Net revenue | $ | 130,234 | $ | 117,316 | $ | 240,210 | $ | 224,958 | ||||||||
| Cost of goods sold | 29,198 | 26,316 | 57,894 | 52,923 | ||||||||||||
| Gross profit | 101,036 | 91,000 | 182,316 | 172,035 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Selling, general and administrative | 76,540 | 70,317 | 148,862 | 144,151 | ||||||||||||
| Research and development | 15,587 | 10,938 | 28,397 | 22,140 | ||||||||||||
| Impairment of property and construction | 18,842 | — | 18,842 | — | ||||||||||||
| Write down of capitalized internal-use software costs | 3,959 | — | 3,959 | — | ||||||||||||
| Total operating expenses | 114,928 | 81,255 | 200,060 | 166,291 | ||||||||||||
| Income (loss) from operations | (13,892 | ) | 9,745 | (17,744 | ) | 5,744 | ||||||||||
| Other expense, net: | ||||||||||||||||
| Interest expense, net | (620 | ) | (594 | ) | (1,134 | ) | (1,243 | ) | ||||||||
| Other income (expense), net | (28 | ) | 28 | (5 | ) | 51 | ||||||||||
| Total other expense, net | (648 | ) | (566 | ) | (1,139 | ) | (1,192 | ) | ||||||||
| Net income (loss) before income taxes | (14,540 | ) | 9,179 | (18,883 | ) | 4,552 | ||||||||||
| Income tax expense | (2,503 | ) | (3,863 | ) | (260 | ) | (2,205 | ) | ||||||||
| Net income (loss) and comprehensive income (loss) | $ | (17,043 | ) | $ | 5,316 | $ | (19,143 | ) | $ | 2,347 | ||||||
| Net income (loss) per share: | ||||||||||||||||
| Basic | $ | (0.13 | ) | $ | 0.04 | $ | (0.14 | ) | $ | 0.02 | ||||||
| Diluted | $ | (0.13 | ) | $ | 0.04 | $ | (0.14 | ) | $ | 0.02 | ||||||
| Weighted-average common shares outstanding | ||||||||||||||||
| Basic | 132,573,153 | 131,293,398 | 132,217,463 | 131,189,405 | ||||||||||||
| Diluted | 132,573,153 | 133,066,010 | 132,217,463 | 132,475,908 | ||||||||||||
| ORGANOGENESIS HOLDINGS INC. UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS | ||||||||
| (amounts in thousands, except share and per share data) | ||||||||
| Six Months Ended June 30, | ||||||||
| 2024 | 2023 | |||||||
| Cash flows from operating activities: | ||||||||
| Net income (loss) | $ | (19,143 | ) | $ | 2,347 | |||
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | ||||||||
| Depreciation and amortization | 6,438 | 4,922 | ||||||
| Amortization of intangible assets | 1,735 | 2,459 | ||||||
| Reduction in the carrying value of right-of-use assets | 4,364 | 3,893 | ||||||
| Non-cash interest expense | 209 | 215 | ||||||
| Deferred interest expense | 213 | 245 | ||||||
| Provision recorded for credit losses | 2,032 | 190 | ||||||
| Deferred tax benefit | (5,689 | ) | — | |||||
| Loss on disposal of property and equipment | 434 | 65 | ||||||
| Adjustment for excess and obsolete inventories | 4,469 | 3,464 | ||||||
| Stock-based compensation | 4,975 | 4,213 | ||||||
| Impairment of property and construction (Note 6) | 18,842 | — | ||||||
| Write down of capitalized internal-use software costs (Note 6) | 3,959 | — | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | (25,978 | ) | (4,970 | ) | ||||
| Inventories | (2,009 | ) | (4,045 | ) | ||||
| Prepaid expenses and other current assets and other assets | (436 | ) | (2,874 | ) | ||||
| Operating leases | (5,908 | ) | (4,178 | ) | ||||
| Accounts payable | (2,147 | ) | (3,535 | ) | ||||
| Accrued expenses and other current liabilities | 8,162 | 1,091 | ||||||
| Other liabilities | 54 | 67 | ||||||
| Net cash provided by (used in) operating activities | (5,424 | ) | 3,569 | |||||
| Cash flows from investing activities: | ||||||||
| Purchases of property and equipment | (4,102 | ) | (15,061 | ) | ||||
| Net cash used in investing activities | (4,102 | ) | (15,061 | ) | ||||
| Cash flows from financing activities: | ||||||||
| Payments of term loan under the 2021 Credit Agreement | (2,813 | ) | (1,875 | ) | ||||
| Payments of withholding taxes in connection with RSUs vesting | (1,174 | ) | (332 | ) | ||||
| Proceeds from the exercise of stock options | 180 | — | ||||||
| Principal repayments of finance lease obligations | (528 | ) | (83 | ) | ||||
| Net cash used in financing activities | (4,335 | ) | (2,290 | ) | ||||
| Change in cash, cash equivalents and restricted cash | (13,861 | ) | (13,782 | ) | ||||
| Cash, cash equivalents, and restricted cash, beginning of period | 104,338 | 103,290 | ||||||
| Cash, cash equivalents, and restricted cash, end of period | $ | 90,477 | $ | 89,508 | ||||
| Supplemental disclosure of cash flow information: | ||||||||
| Cash paid for interest | $ | 2,744 | $ | 2,608 | ||||
| Cash paid for income taxes | $ | 4,796 | $ | 3,022 | ||||
| Supplemental disclosure of non-cash investing and financing activities: | ||||||||
| Cumulative effect adjustment for adoption of ASU No. 2016-13 | $ | — | $ | 615 | ||||
| Purchases of property and equipment included in accounts payable and accrued expenses | $ | 709 | $ | 1,882 | ||||
| Right-of-use assets obtained through operating lease obligations | $ | 817 | $ | 4,253 | ||||
Non-GAAP Financial Measures
Our management uses financial measures that are not in accordance with generally accepted accounting principles in the United States, or GAAP, in addition to financial measures in accordance with GAAP to evaluate our operating results. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with GAAP. Our management uses Adjusted EBITDA, adjusted net income (loss), and non-GAAP operating income to evaluate our operating performance and trends and make planning decisions. Our management believes Adjusted EBITDA, adjusted net income (loss), and non-GAAP operating income help identify underlying trends in our business that could otherwise be masked by the effect of the items that we exclude. Accordingly, we believe that Adjusted EBITDA, adjusted net income (loss), and non-GAAP operating income provide useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and prospects, and allowing for greater transparency with respect to key financial metrics used by our management in its financial and operational decision-making.
The following table presents a reconciliation of GAAP net income (loss) to non-GAAP EBITDA and non-GAAP Adjusted EBITDA, for the periods presented:
| ` | Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| (Unaudited, in thousands) | ||||||||||||||||
| Net income (loss) | $ | (17,043 | ) | $ | 5,316 | $ | (19,143 | ) | $ | 2,347 | ||||||
| Interest expense, net | 620 | 594 | 1,134 | 1,243 | ||||||||||||
| Income tax expense | 2,503 | 3,863 | 260 | 2,205 | ||||||||||||
| Depreciation and amortization | 3,366 | 2,228 | 6,438 | 4,922 | ||||||||||||
| Amortization of intangible assets | 834 | 1,229 | 1,735 | 2,459 | ||||||||||||
| EBITDA | (9,720 | ) | 13,230 | (9,576 | ) | 13,176 | ||||||||||
| Stock-based compensation expense | 2,568 | 2,299 | 4,975 | 4,213 | ||||||||||||
| Restructuring charge (1) | — | (126 | ) | — | 1,782 | |||||||||||
| Impairment of building and improvements (2) | 18,842 | — | 18,842 | — | ||||||||||||
| Write-down of capitalized software costs (3) | 3,959 | — | 3,959 | — | ||||||||||||
| Adjusted EBITDA | $ | 15,649 | $ | 15,403 | $ | 18,200 | $ | 19,171 | ||||||||
(1) Amount reflects employee severance, retention and benefits as well as other exit costs associated with the Company’s restructuring activities. (2) Amount reflects the impairment of a purchased building and associated unfinished construction work. (3) Amount reflects the write-down of costs previously capitalized in the development of internal-use software, that the Company determined have no future value. | ||||||||||||||||
The following table presents a reconciliation of GAAP net income (loss) to non-GAAP adjusted net income (loss), for the periods presented:
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| (Unaudited, in thousands) | ||||||||||||||||
| Net income (loss) | $ | (17,043 | ) | $ | 5,316 | $ | (19,143 | ) | $ | 2,347 | ||||||
| Amortization | 834 | 1,229 | 1,735 | 2,459 | ||||||||||||
| Restructuring charge (1) | — | (126 | ) | — | 1,782 | |||||||||||
| Impairment of building and improvements (2) | 18,842 | — | 18,842 | — | ||||||||||||
| Write-down of capitalized software costs (3) | 3,959 | — | 3,959 | — | ||||||||||||
| Tax on above | (6,381 | ) | (298 | ) | (6,625 | ) | (1,145 | ) | ||||||||
| Adjusted net income (loss) | $ | 211 | $ | 6,121 | $ | (1,232 | ) | $ | 5,443 | |||||||
(1) Amount reflects employee severance, retention and benefits as well as other exit costs associated with the Company’s restructuring activities. (2) Amount reflects the impairment of a purchased building and associated unfinished construction work. (3) Amount reflects the write-down of costs previously capitalized in the development of internal-use software, that the Company determined have no future value. | ||||||||||||||||
The following table presents a reconciliation of GAAP income (loss) from operations to non-GAAP operating income, for the periods presented:
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| (Unaudited, in thousands) | ||||||||||||||||
| Income (loss) from operations | $ | (13,892 | ) | $ | 9,745 | $ | (17,744 | ) | $ | 5,744 | ||||||
| Amortization of intangible assets | 834 | 1,229 | 1,735 | 2,459 | ||||||||||||
| Restructuring charge (1) | — | (126 | ) | — | 1,782 | |||||||||||
| Impairment of building and improvements (2) | 18,842 | — | 18,842 | — | ||||||||||||
| Write-down of capitalized software costs (3) | 3,959 | — | 3,959 | — | ||||||||||||
| Non-GAAP operating income | $ | 9,743 | $ | 10,848 | $ | 6,792 | $ | 9,985 | ||||||||
(1) Amount reflects employee severance, retention and benefits as well as other exit costs associated with the Company’s restructuring activities. (2) Amount reflects the impairment of a purchased building and associated unfinished construction work. (3) Amount reflects the write-down of costs previously capitalized in the development of internal-use software, that the Company determined have no future value. | ||||||||||||||||
The following table presents a reconciliation of projected GAAP net income (loss) to projected non-GAAP EBITDA and projected non-GAAP Adjusted EBITDA included in our guidance for the year ending December 31, 2024:
| Year Ended December 31, | ||||||||
| 2024L | 2024H | |||||||
| Net loss | $ | (27,000 | ) | $ | (12,000 | ) | ||
| Interest expense, net | 3,000 | 2,000 | ||||||
| Income tax expense | (6,000 | ) | (1,000 | ) | ||||
| Depreciation and amortization | 10,000 | 10,000 | ||||||
| Amortization of intangible assets | 3,000 | 3,000 | ||||||
| EBITDA | $ | (17,000 | ) | $ | 2,000 | |||
| Stock-based compensation expense | 10,000 | 10,000 | ||||||
| Impairment of building and improvements | 19,000 | 19,000 | ||||||
| Write-down of capitalized software costs | 4,000 | 4,000 | ||||||
| Adjusted EBITDA | $ | 16,000 | $ | 35,000 | ||||
The following table presents a reconciliation of projected GAAP net loss to projected non-GAAP adjusted net income (loss) included in our guidance for the year ending December 31, 2024:
| Year Ending December 31, | ||||||||
| 2024L | 2024H | |||||||
| Net loss | $ | (27,000 | ) | $ | (12,000 | ) | ||
| Amortization of intangible assets | 3,000 | 3,000 | ||||||
| Impairment of building and improvements | 19,000 | 19,000 | ||||||
| Write-down of capitalized software costs | 4,000 | 4,000 | ||||||
| Tax on above | (7,000 | ) | (7,000 | ) | ||||
| Adjusted net income (loss) | $ | (8,000 | ) | $ | 7,000 | |||
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include statements relating to the Company’s expected revenue, net income (loss), adjusted net income (loss), EBITDA, and Adjusted EBITDA for fiscal 2024 and the breakdown of expected revenue in both its Advanced Wound Care and Surgical & Sports Medicine categories. Forward-looking statements with respect to the operations of the Company, strategies, prospects, and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: (1) the impact of any changes to the coverage and reimbursement levels for the Company’s products (including as a result of the recently proposed LCDs); (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause the Company’s products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete; (4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company’s ability to raise funds to expand its business; (6) the Company has incurred losses in the current period and prior periods and may incur losses in the future; (7) changes in applicable laws or regulations; (8) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (9) the Company’s ability to maintain production or obtain supply of its products in sufficient quantities to meet demand; (10) any resurgence of the COVID-19 pandemic and its impact, if any, on the Company’s fiscal condition and results of operations; (11) the impact of the suspension of commercialization of: (a) ReNu and NuCel in connection with the expiration of the FDA’s enforcement grace period for HCT/Ps on May 31, 2021 and (b) Dermagraft in the second quarter of 2022 pending transition of manufacturing to a new manufacturing facility or a third-party manufacturer; (12) whether the Company is able to obtain regulatory approval for and successfully commercialize ReNu; and (13) other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including Item 1A (Risk Factors) of the Company’s Form 10-K for the year ended December 31, 2023 and its subsequently filed periodic reports. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit www.organogenesis.com.
FAQ
What were Organogenesis Holdings' Q2 2024 financial results?
How did ORGO's Advanced Wound Care product revenue perform in Q2 2024?
What was the revenue change for Surgical & Sports Medicine products in Q2 2024?
What is Organogenesis Holdings' 2024 revenue guidance?
What were the major factors affecting ORGO's operating expenses in Q2 2024?
